Lifeward shares rise 11.20% intraday after acquiring Oramed's POD™ technology targeting $600B injectable market and securing $47M in strategic funding.

Lifeward surged 11.20% intraday, driven by a strategic partnership with Oramed to acquire its proprietary oral drug delivery technology (POD™) targeting the $60+ billion injectable drug market. Oramed became a major shareholder via a $18 million convertible note and 49.9% equity stake, while Lifeward secured $47 million in strategic funding to expand profitability and diversify operations. The company’s FDA-certified medical robotics products, ReWalk® and AlterG®, generated $26 million in revenue over the past four quarters, forming a foundational business base.